PD-L2 Adds Value to Immunotherapy Prediction in Head and Neck Cancers, Merck Study Finds – GenomeWeb
|
PD-L2 Adds Value to Immunotherapy Prediction in Head and Neck Cancers, Merck Study Finds
GenomeWeb NEW YORK (GenomeWeb) – A new study in Clinical Cancer Research has shown that certain cancer patients with altered PD-L2 expression may do better when treated with PD-1 targeting immunotherapy regardless of their levels of PD-L1, which is the … |
